News & Updates

New drug applications approved by US FDA as of 01-15 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Uncontrolled postpartum haemorrhage (PPH) is a life-threatening complication of childbirth that is temporarily managed with uterine balloon tamponade. At SMFM 2023, researchers from the US presented findings for a new device that could control PPH safely and effectively in just 5 minutes.

Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.

The selective neurokinin (NK)-1,3 receptor antagonist elinzanetant appears to be beneficial in the treatment of vasomotor symptoms (VMS) and associated sleep disturbance in postmenopausal women, as shown in the results of the phase IIb SWITCH-1 trial.

Coronary artery disease appears to be common among women with a history of adverse pregnancy outcomes, including those estimated to be at low risk of cardiovascular disease, according to a study.